TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27906432
Drug: Concurrent radio
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent radio chemotherapy and hypofractionation (DT of 42.56 Gy, 2.66Gy/fraction, 16 times, during 22-24 days)
Study: 23910578
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment with FEIBA NF
Study: 20493549
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 mg, 4 mg, or 8 mg once daily)
Study: 15832627
Drug: Deeper processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deeper processing during encoding (semantic, phonemic, or graphemic questions) for twice-presented items
Study: 2505712
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg orally
Study: 2505712
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg orally
Study: 2505712
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg orally
Study: 25774559
Drug: Compliance Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance Therapy (up to six weekly sessions)
Study: 19081418
Drug: ABT-335 +
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 + simvastatin 20 mg
Study: 19081418
Drug: ABT-335 +
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 + simvastatin 40 mg
Study: 19081418
Drug: ABT-335 monotherapy
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-335 monotherapy (135 mg)
Study: 8942424
Drug: 3,4-didehydroretinyl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,4-didehydroretinyl acetate (DRA) administered at standard doses: 5.3 mumol for children < 6 y, 7.0 mumol for children 6-12 y, 8.8 mumol for adults and children > 12 y.
Study: 8942424
Drug: DRA in
Normalized name: EPHEDRA INTERMEDIA STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRA in vitamin E-containing corn oil, with or without 4.6 mmol all-rac-alpha-tocopheryl acetate/L.
Study: 1848053
Drug: Towne live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Towne live attenuated virus vaccine
Study: 6220334
Drug: Almitrine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (60 mg/24 h)
Study: 6220334
Drug: Raubasine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raubasine (20 mg/24 h)
Study: 29324776
Drug: Control (direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (direct infertility treatment)
Study: 26528775
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg + placebo
Study: 24656590
Drug: Intratendinous injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRATENDINOUS LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratendinous injection of platelet-rich plasma (PRP) under ultrasound (US) guidance
Study: 11870792
Drug: Long pulsed
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long pulsed Nd:YAG laser treatment (1-5 sessions)
Study: 11870792
Drug: Long pulsed
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long pulsed Nd:YAG laser treatment (5 sessions)
Study: 11870792
Drug: Long pulsed
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long pulsed Nd:YAG laser treatment
Study: 2134116
Drug: Oxiracetam (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam (800 mg t.i.d.)
Study: 30368018
Drug: Fulranumab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulranumab (9 mg)
Study: 24804272
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion protocol (transfusion if hemoglobin dropped below 9.9 g dL(-1))
Study: 24804272
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion protocol (transfusion if hemoglobin dropped below 7.7 g dL(-1))
Study: 30049303
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of Mirogabalin 15 mg with Metformin 850 mg
Study: 11995260
Drug: Montelukast (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5-10 mg once daily for three months)
Study: 10784382
Drug: Chronic supplementation
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic supplementation with 15 g of arginine aspartate daily for 14 days
Study: 7568859
Drug: Uniphasic injection
Normalized name: insulin isophane, pork / insulin, regular, pork Injectable Suspension [Hypurin Porcine Biphasic Isophane]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphasic injection of 38 g of iodine
Study: 7568859
Drug: Uniphasic injection
Normalized name: insulin isophane, pork / insulin, regular, pork Injectable Suspension [Hypurin Porcine Biphasic Isophane]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphasic injection of 26 g of iodine
Study: 7568859
Drug: Biphasic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic injection
Study: 2122131
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with mitomycin C (MMC), tegafur, and PSK
Study: 7427705
Drug: Tetracycline 250
Normalized name: tetracycline 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 250 mg four times daily for seven days
Study: 7427705
Drug: Tetracycline 500
Normalized name: oxytetracycline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 500 mg four times daily for seven days
Study: 7427705
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (250 mg and 500 mg)
Study: 31647886
Drug: Supplemental whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental whey protein (PRO) 25 g, 3×/day for 12 weeks
Study: 31647886
Drug: Isocaloric placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric placebo (PLA) 25 g, 3×/day for 12 weeks
Study: 30069754
Drug: Mental health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental health conditions (e.g., schizophrenia, obsessive compulsive disorder)
Study: 17609405
Drug: Proinsulin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinsulin levels >5 pmol/l with blood glucose levels <2.5 mmol/l during a 72 h fast test
Study: 17609405
Drug: C-peptide levels
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide levels >0.2 nmol/l
Study: 17609405
Drug: Proinsulin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinsulin levels >22 pmol/l
Study: 17609405
Drug: Proinsulin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proinsulin levels <22 pmol/l
Study: 15308521
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral azithromycin for 13 weeks (1 g single dose for Chlamydia infection)
Study: 11355895
Drug: rEpo administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rEpo administration (30 IU/kg)
Study: 11355895
Drug: rEpo administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rEpo administration (various treatments)
Study: 11355895
Drug: Multiparametric formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiparametric formula including hematocrit value, reticulocyte count, soluble transferrin receptor content, and beta-globin mRNA concentration
Study: 27809891
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 1200 mg/day
Study: 9743816
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 3 x 400 mg/day
Study: 3382159
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g I.V. as a single injection performed 1 hour before ESWL
Study: 29911435
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) therapy recommendations
Study: 29911435
Drug: Medication administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication administration record (MAR) recommendations
Study: 18652326
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at Jingming (BL 1), Taiyang (EX‐HN 5), Chengqi (ST 1), Hegu (LI4)
Study: 18652326
Drug: Eye drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drug treatment with local dropping of Aiweiduo
Study: 18652326
Drug: Eye drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drug treatment
Study: 16409197
Drug: Subcutaneous specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous specific immunotherapy (SIT) with house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) at maintenance doses of 20, 2,000, and 20,000 SQ‐U weekly for 1 year.
Study: 16409197
Drug: Subcutaneous specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous specific immunotherapy (SIT) with house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) at higher doses (2,000 and 20,000 SQ‐U).
Study: 15199077
Drug: DRF-1042 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRF-1042 at 120 mg/m(2)/day
Study: 15199077
Drug: DRF-1042 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRF-1042 at 1.5 to 270 mg/m(2)
Study: 7930386
Drug: Clomipramine 50
Normalized name: clomiPRAMINE 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 50 mg orally 2 hours before blood collection
Study: 3286384
Drug: famotidine 10
Normalized name: famotidine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 10 mg bolus injection iv followed by continuous infusions of 3.2 mg/h
Study: 3286384
Drug: famotidine 10
Normalized name: famotidine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 10 mg bolus injection iv followed by continuous infusions of 4 mg/h
Study: 19140646
Drug: Working memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Working memory training (twice weekly for 3 months)
Study: 16766587
Drug: TAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC with primary prophylactic G-CSF (PPG)
Study: 10404768
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives or hormone replacement therapy
Study: 2672868
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine (30 mg)
Study: 333601
Drug: Parenteral cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral cefazolin begun before operation
Study: 333601
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic present in the tissues at the time of inoculation or resistant bacteria
Study: 28720980
Drug: Cognitive Rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Rehabilitation Therapy (CRT)
Study: 26200164
Drug: Xenograft (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xenograft (1 g) + porous titanium (1 g) granules (Natix; Tigran Technologies AB)
Study: 21987227
Drug: Modular cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular cognitive behavioral therapy (CBT)
Study: 20151520
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous analgesia
Study: 17164979
Drug: High flavanol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavanol cocoa (329 mg flavanols, 61 mg epicatechin per 100 ml)
Study: 17164979
Drug: Low flavanol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavanol cocoa (27 mg flavanols, 6.6 mg epicatechin per 100 ml)
Study: 22317387
Drug: Improved land
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved land preparation tools (clod breaker, improved plough/'danella')
Study: 22317387
Drug: Improved land
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved land preparation tools
Study: 19172341
Drug: Ribonuclease-enriched lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribonuclease-enriched lactoferrin (R-ELF) supplement
Study: 11848031
Drug: Immunotherapy using
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy using allogenic leukocytes from the partner
Study: 9394162
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glucose, amino acids, and emulsion enriched in essential fatty acids (EFAs)
Study: 25692479
Drug: cpTi implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: cpTi implants
Study: 25692479
Drug: TiZr and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiZr and cpTi implants
Study: 24971004
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin (PRM) 2 mg nightly for 24 weeks
Study: 24971004
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin (PRM) 2 mg nightly for 24 weeks in comorbid insomnia subgroup
Study: 23060506
Drug: no vaccine
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: no vaccine
Study: 18668682
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily for 10 weeks
Study: 18668682
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg twice daily for 10 weeks
Study: 15129926
Drug: 1000 mg/d
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/d of supplemental calcium
Study: 11794170
Drug: Additional localized
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional localized dose of 16 Gy radiation (given in eight fractions by external electron beam)
Study: 11794170
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (50 Gy radiation to the whole breast)
Study: 11794170
Drug: Additional localized
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional localized dose of 16 Gy radiation (for patients 40 years old or younger)
Study: 11794170
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (for patients 40 years old or younger)
Study: 11794170
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (for patients aged 41 to 50 years)
Study: 29614276
Drug: 1-dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-dose misoprostol
Study: 29614276
Drug: multiple-dose misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: multiple-dose misoprostol
Study: 27450392
Drug: Valaciclovir (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (2 g QDS or reduced according to renal function) for 6 months
Study: 27450392
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment for 6 months
Study: 23764238
Drug: 200mg TSU-68
Normalized name: TSUGA CANADENSIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg TSU-68 twice daily
Study: 10396718
Drug: 10-ml 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-ml 0.125% bupivacaine administered twice daily for 4 days
Study: 10396718
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered twice daily for 4 days
Study: 10396718
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received treatment
Study: 10396718
Drug: 10-ml 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-ml 0.125% bupivacaine administered
Study: 2328177
Drug: Tubocurarine 0.4‐0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubocurarine 0.4‐0.5 mg kg‐1
Study: 2328177
Drug: Pancuronium 0.07‐0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.07‐0.08 mg kg‐1
Study: 2328177
Drug: Alcuronium 0.2‐0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0.2‐0.3 mg kg‐1
Study: 30371552
Drug: Pure unilateral
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure unilateral rhythmic movement therapy consisting of 12 sessions over 1 month, involving straight or circular rhythmic movements with robotic assistance.
Study: 23481119
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (leuprolide)
Study: 11491421
Drug: Amprenavir 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir 900 mg twice daily
Study: 11491421
Drug: Amprenavir 1050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir 1050 mg twice daily
Study: 11491421
Drug: Amprenavir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir 1200 mg twice daily
Study: 11491421
Drug: Amprenavir/Abacavir 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir/Abacavir 900 mg twice daily (combination therapy)
Study: 9536859
Drug: beta-carotene (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene (40 mg)
Study: 9536859
Drug: lycopene (38
Approvals — FDA: no, EMA: no, PMDA: no
Description: lycopene (38 mg)
Study: 9536859
Drug: lutein (31.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lutein (31.2 mg)
Study: 7625111
Drug: Oral RRV-TV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral RRV-TV rotavirus vaccine with IPV
Study: 7625111
Drug: Oral RRV-TV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral RRV-TV rotavirus vaccine with OPV
Study: 2773899
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (BSS) 30 ml (525 mg) q.i.d. for 21 days
Study: 152612
Drug: 1% 6‐aminonicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% 6‐aminonicotinamide (6‐AN) gel
Study: 152612
Drug: Topical 6‐AN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 6‐AN and oral niacinamide therapy
Study: 152612
Drug: Topical 6‐AN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 6‐AN
Study: 29587297
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized amikacin (0.2 g) treatment twice daily for 2 weeks along with intravenous antibiotic therapy
Study: 22959905
Drug: DMPA-SC (104
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA-SC (104 mg administered at baseline and 12 weeks later)
Study: 20625123
Drug: Methylphenidate (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (54 mg/d)
Study: 18581018
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg of rocuronium
Study: 10595696
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg once daily (o.d.)
Study: 7113312
Drug: Profenid (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profenid (3 capsules + 1 suppositorium)
Study: 7113312
Drug: Indomethacin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (3 capsules + 1 suppositorium)
Study: 30962094
Drug: Japanese encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese encephalitis vaccine IXIARO®
Study: 30962094
Drug: Japanese encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese encephalitis vaccine IXIARO® with TBE vaccination
Study: 30962094
Drug: Japanese encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese encephalitis vaccine IXIARO® without TBE vaccination
Study: 28533517
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg vortioxetine for 14 days
Study: 22175765
Drug: Specific IgE
Normalized name: BSA specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgE ≥0.35 kU(A)/l for hazelnut
Study: 22175765
Drug: Specific IgE
Normalized name: BSA specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgE cutoff of 26 kU(A)/l
Study: 20179669
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g per day) plus dietary treatment
Study: 17920338
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg 3 times a day for 6 weeks
Study: 15704047
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily plus omeprazole 20 mg once daily
Study: 12842242
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg once daily
Study: 12842242
Drug: Eplerenone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 200 mg once daily
Study: 8885731
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (5 mg orally, every 4 hours)
Study: 28070770
Drug: Immediate dance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate dance intervention (10 private weekly dance lessons and 2 practice parties over 12 weeks)
Study: 12597061
Drug: Fondaparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (2.5 mg once daily, subcutaneous, starting postoperatively)